Buy, Sell or Hold: Pfizer Inc (PFE-N) — Stock Predictions at Stockchase

NYSE:PFE

42.14

0.82 (1.97%) 1d

Showing 1 to 15 of 721 entries

BUY

All healthcare stocks have been pressured. PFE is protected by their near-4% dividend. We will all need their Covid booster shot.

biotechnology / pharmaceutical

WEAK BUY

The performance has been disappointing. The problem with big, old pharma is that it is not enough to move the needle. He thinks it is a good one to put away. They are a little constrained on the new product side. He'd suggest an ETF of biotech companies.

biotechnology / pharmaceutical

BUY

Great dividend yield, not trading at a high multiple. Not a pure play. Covid vaccine issue will continue for years to come. Likes healthcare, but it tends to come up as a US political issue. A great story here. He owns JNJ instead.

biotechnology / pharmaceutical

WEAK BUY

Good quality stock that won't hurt you. Reasonable valuation, nice dividend. Bad news is everything is already built into the stock. Where's the growth past 2023? Not much upside. He'd add at $32-36, but not here at $44.

biotechnology / pharmaceutical

DON'T BUY

A broad company with many types of drugs. Laws in the US stipulates that after spending millions of dollar for franchises, the drug will go off patent in time. Pharmaceuticals have been doing this for a long time.

biotechnology / pharmaceutical

BUY

It looks good it will get FDA approval for a Covid vaccine for children. Any good news here will help PFE. He's owned this for a while. The current pullback is a buying opportunity.

biotechnology / pharmaceutical

BUY

Many reasons to like this including booster shots which will help shares (though Moderna will benefit more). This has pulled back a but, she likes it here. Has value.

biotechnology / pharmaceutical

COMMENT

The New York Times reports that the FDA will give full approval to Pfizer's Covid vaccine (for booster shots). He wouldn't rush in after-hours to buy Pfizer, because he's wary of such after-hours moves. Such trading is thin, low-volume.

biotechnology / pharmaceutical

BUY

It's been on a hot run. The Delta variant gives them a huge tailwind, because Washington is about to mandate Covid booster shots. Pfizer needs it, because they're about to lose the patents on some of their major drugs. Annual booster shots would give Pfizer a giant revenue stream. Shares are up 22% in the past month.

biotechnology / pharmaceutical

Unlock Panic-Proof Portfolio and Top Stock Picks

Become a member Or, Sign In

PAST TOP PICK

(A Top Pick Sep 24/20, Up 39%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with PFE is progressing well. We now recommend trailing up the stop (from $33) to $42. If triggered this would all but guarantee a investment return over 17%, when including the previous recommendation to cover half.

biotechnology / pharmaceutical

DON'T BUY

Likes it under $40-$36. A bit overbought right now. A good value play and dividend player but would not chase it here. There is probably limited upside here.

biotechnology / pharmaceutical

BUY

Opportunity for Pfizer and J&J are solid. You give up some appreciation when you select a stock with higher yield. However, total return is the most important. There is more diversification with JNJ with medical supplies. Pfizer's partnership with BioNtech is positive. There is renewed chatter about drug price controls. Both offer good prospective.

biotechnology / pharmaceutical

WAIT

They report Tuesday. Despite a successful Covid drug, the stock has done nothing because they have a slew of patents about to expire. That said, it's a fine stock with good managers and a safe dividend yield. You could to a lot worse. You would wait before the report.

biotechnology / pharmaceutical

DON'T BUY

Not overly bullish on healthcare as a whole, as its growth may be less attractive. Likes medical devices, with a built-in backlog due to Covid. He owns SYK. There should be a significant pickup in procedures over the next 2 years. SYK has strong earnings growth, near a 1-year high. Also look at IHI, the medical devices ETF, packed with companies leading the healthcare sector.

biotechnology / pharmaceutical

DON'T BUY

Their vaccine has been a boon to their revenues, which jumped 30% in a one year, but this is likely a round trip. Also, margins on this vaccine are fairly low. The vaccine offers some benefit to PFE, but it's limited. Look elsewhere.

biotechnology / pharmaceutical

Showing 1 to 15 of 721 entries

Pfizer Inc(PFE-N) Rating

Ranking : 5 out of 5

Bullish - Buy Signals / Votes : 16

Neutral - Hold Signals / Votes : 1

Bearish - Sell Signals / Votes : 13

Total Signals / Votes : 30

Stockchase rating for Pfizer Inc is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Pfizer Inc(PFE-N) Frequently Asked Questions

What is Pfizer Inc stock symbol?

Pfizer Inc is a American stock, trading under the symbol PFE-N on the New York Stock Exchange (PFE). It is usually referred to as NYSE:PFE or PFE-N

Is Pfizer Inc a buy or a sell?

In the last year, 30 stock analysts published opinions about PFE-N. 16 analysts recommended to BUY the stock. 13 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Pfizer Inc.

Is Pfizer Inc a good investment or a top pick?

Pfizer Inc was recommended as a Top Pick by on . Read the latest stock experts ratings for Pfizer Inc.

Why is Pfizer Inc stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Pfizer Inc worth watching?

30 stock analysts on Stockchase covered Pfizer Inc In the last year. It is a trending stock that is worth watching.

What is Pfizer Inc stock price?

On 2021-10-19, Pfizer Inc (PFE-N) stock closed at a price of $42.135.

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : hello@stockchase.com.